{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["2021"],"submitter":["Karina K"],"pubmed_abstract":["<h4>Introduction</h4>Elevated concentration of proinflammatory cytokines followed by hyperinflammation is one of the hallmarks of severe and critical COVID-19. In the short term, this may result in ARDS and lung injury; subsequently, this may cause pulmonary fibrosis-a disease with poor prognosis-in the long run. Among the cytokines, interleukin-1<i>β</i> (IL-1<i>β</i>) is one of the most overexpressed in COVID-19. We speculate that administration of intravenous activated autologous platelet-rich plasma (aaPRP), which contains interleukin-1 receptor antagonist (IL-1RA), would lower IL-1<i>β</i> levels and benefit the severe and critical COVID-19 patients.<h4>Methods</h4>After acquiring ethical clearance, we recruited 12 adult COVID-19 patients of both sexes from the Koja Regional Hospital "],"journal":["Scientifica"],"pagination":["9427978"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8266471"],"repository":["biostudies-literature"],"pubmed_title":["The Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on \"Profibrotic Cytokine\" IL-1<i>β</i> Levels in Severe and Critical COVID-19 Patients: A Preliminary Study."],"pmcid":["PMC8266471"],"pubmed_authors":["Fatkhurohman N","Andrew H","Krisandi G","Puspitaningrum N","Zakiyah A","Sobariah S","Ernanda D","Novariani R","Hertati Y","Sulaeha AD","Rosadi I","Widyastuti T","Karina K","Christoffel LM","Afini I","Aini N","Rosliana I","Rosidah S"],"additional_accession":[]},"is_claimable":false,"name":"The Effect of Intravenous Autologous Activated Platelet-Rich Plasma Therapy on \"Profibrotic Cytokine\" IL-1<i>β</i> Levels in Severe and Critical COVID-19 Patients: A Preliminary Study.","description":"<h4>Introduction</h4>Elevated concentration of proinflammatory cytokines followed by hyperinflammation is one of the hallmarks of severe and critical COVID-19. In the short term, this may result in ARDS and lung injury; subsequently, this may cause pulmonary fibrosis-a disease with poor prognosis-in the long run. Among the cytokines, interleukin-1<i>β</i> (IL-1<i>β</i>) is one of the most overexpressed in COVID-19. We speculate that administration of intravenous activated autologous platelet-rich plasma (aaPRP), which contains interleukin-1 receptor antagonist (IL-1RA), would lower IL-1<i>β</i> levels and benefit the severe and critical COVID-19 patients.<h4>Methods</h4>After acquiring ethical clearance, we recruited 12 adult COVID-19 patients of both sexes from the Koja Regional Hospital ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021","modification":"2025-04-04T08:16:12.857Z","creation":"2022-02-10T23:49:51.436Z"},"accession":"S-EPMC8266471","cross_references":{"pubmed":["34306796"],"doi":["10.1155/2021/9427978"]}}